Abstract
As an important part of the immune system, T lymphocytes exhibit undoubtedly an important role in targeting and eradicating cancer. However, despite these characteristics, their natural antitumor response may be insufficient. Numerous clinical trials in terminally ill cancer patients testing the design of novel and efficient immunotherapeutic approaches based on the adoptive transfer of autologous tumor-specific T lymphocytes have shown encouraging results. Moreover, this also led to the approval of engineered T-cell therapies in patients. Herein, we will expand on the development and the use of such strategies using tumor-infiltrating lymphocytes or genetically engineered T-cells. We will also comment on the requirements and potential hurdles encountered when elaborating and implementing such treatments as well as the exciting prospects for this kind of emerging personalized medicine therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ACT :
-
Adoptive Cell Therapy
- ALL :
-
Acute Lymphoblastic Leukemia
- ATP :
-
Adenosine Tri-Phosphate
- BCMA :
-
B Cell Maturation Antigen
- CAR :
-
Chimeric Antigen Receptor
- CD19 :
-
Cluster of Differentiation 19
- CEA :
-
Carcinoembryonic Antigen
- CLL :
-
Chronic Lymphoblastic Leukemia
- CR :
-
Complete Response
- CTLA-4 :
-
Cytotoxic T-Lymphocyte-Associated Protein 4
- HER2 :
-
Human Epidermal Growth Factor Receptor 2
- HLA :
-
Human Leukocyte Antigen
- HPV :
-
Human Papillomavirus
- IL-10 :
-
Interleukin 10
- MART1:
-
Melanoma Antigen Recognized by T cells 1
- MHC:
-
Major Histocompatibility Complex
- MM :
-
Multiple Myeloma
- NCR :
-
Natural Cytotoxicity Receptor
- NK :
-
Natural Killer Cells
- NY-ESO :
-
New York Esophageal Squamous Cell Carcinoma Antigen
- OR :
-
Overall Response
- ORR :
-
Objective Response Rate
- PD1 :
-
Programmed Cell Death Protein 1
- PDL-1 :
-
Programmed Cell Death Ligand Protein 1
- PMEL :
-
Premelanosome Protein
- RCC :
-
Renal Cell Carcinoma
- TAA :
-
Tumor-Associated Antigen
- TCR :
-
T cell Receptor
- TGF :
-
Transforming Growth Factor
- Th2:
-
T helper type 2 lymphocytes
- TIL :
-
Tumor-Infiltrating Lymphocytes
- Tregs :
-
Regulatory T cells
References
Ager A (2017) High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function. Front Immunol 8:45. https://doi.org/10.3389/fimmu.2017.00045
Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H, Kranz DM (2012) Single-chain Valpha Vbeta T-cell receptors function without mispairing with endogenous TCR chains. Gene Ther 19(4):365–374. https://doi.org/10.1038/gt.2011.104
Aksoylar HI, Tijaro-Ovalle NM, Boussiotis VA, Patsoukis N (2020) T cell metabolism in cancer immunotherapy. Immunometabolism 2(3):e200020. https://doi.org/10.20900/immunometab20200020
Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN (2016) T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128(13):1688–1700. https://doi.org/10.1182/blood-2016-04-711903
Alsaiari SK, Qutub SS, Sun S, Baslyman W, Aldehaiman M, Alyami M, Almalik A, Halwani R, Merzaban J, Mao Z, Khashab NM (2021) Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy. Sci Adv 7(4). https://doi.org/10.1126/sciadv.abe7174
Andersen R, Westergaard MCW, Kjeldsen JW, Muller A, Pedersen NW, Hadrup SR, Met O, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM (2018) T-cell responses in the microenvironment of primary renal cell carcinoma-implications for adoptive cell therapy. Cancer Immunol Res 6(2):222–235. https://doi.org/10.1158/2326-6066.CIR-17-0467
Andrews LP, Yano H, Vignali DAA (2019) Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol 20(11):1425–1434. https://doi.org/10.1038/s41590-019-0512-0
Ankri C, Cohen CJ (2014) Out of the bitter came forth sweet: activating CD28-dependent co-stimulation via PD-1 ligands. Onco Targets Ther 3(1):e27399. https://doi.org/10.4161/onci.27399
Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ (2013) Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol 191(8):4121–4129. https://doi.org/10.4049/jimmunol.1203085
Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF (2014) Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22(3):623–633. https://doi.org/10.1038/mt.2013.262
Audehm S, Glaser M, Pecoraro M, Braunlein E, Mall S, Klar R, Effenberger M, Albers J, Bianchi HO, Peper J, Yusufi N, Busch DH, Stevanovic S, Mann M, Antes I, Krackhardt AM (2019) Key features relevant to select antigens and TCR from the MHC-mismatched repertoire to treat cancer. Front Immunol 10:1485. https://doi.org/10.3389/fimmu.2019.01485
Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18(1):59. https://doi.org/10.1186/s12964-020-0530-4
Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ (2002) Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62(16):4690–4695
Barnard ND (1992) The AMA and the physicians committee for responsible medicine. JAMA 268(6):788–789
Beatty PR, Krams SM, Martinez OM (1997) Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 158(9):4045–4051
Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN (2013) Blockade of TGF-beta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol 191(6):3232–3239. https://doi.org/10.4049/jimmunol.1301270
Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen JB, Schumacher TN (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16(5):565–570. https://doi.org/10.1038/nm.2128
Besser MJ, Itzhaki O, Ben-Betzalel G, Zippel DB, Zikich D, Kubi A, Brezinger K, Nissani A, Levi M, Zeltzer LA, Ben-Nun A, Asher N, Shimoni A, Nagler A, Markel G, Shapira-Frommer R, Schachter J (2020) Comprehensive single institute experience with melanoma TIL: long term clinical results, toxicity profile, and prognostic factors of response. Mol Carcinog 59(7):736–744. https://doi.org/10.1002/mc.23193
Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16(9):2646–2655. https://doi.org/10.1158/1078-0432.CCR-10-0041
Besser H, Yunger S, Merhavi-Shoham E, Cohen CJ, Louzoun Y (2019) Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides. J Immunother Cancer 7(1):135. https://doi.org/10.1186/s40425-019-0595-z
Bethune MT, Gee MH, Bunse M, Lee MS, Gschweng EH, Pagadala MS, Zhou J, Cheng D, Heath JR, Kohn DB, Kuhns MS, Uckert W, Baltimore D (2016) Domain-swapped T cell receptors improve the safety of TCR gene therapy. elife 5. https://doi.org/10.7554/eLife.19095
Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ (2010) Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 184(11):6232–6241
Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM (2018) Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J Clin Oncol 36(11):1128–1139. https://doi.org/10.1200/JCO.2017.74.3179
Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24(5):657–671. https://doi.org/10.1016/j.cmet.2016.08.011
Bright RK, Bright JD, Byrne JA (2014) Overexpressed oncogenic tumor-self antigens. Hum Vaccin Immunother 10(11):3297–3305. https://doi.org/10.4161/hv.29475
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN (2018) T cells genetically modified to express an anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J ClinOncol 36(22):2267–2280. https://doi.org/10.1200/JCO.2018.77.8084
Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 6(1):53. https://doi.org/10.1038/s41392-021-00487-6
Bunse M, Bendle GM, Linnemann C, Bies L, Schulz S, Schumacher TN, Uckert W (2014) RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther 22(11):1983–1991. https://doi.org/10.1038/mt.2014.142
Carter JA, Preall JB, Grigaityte K, Goldfless SJ, Jeffery E, Briggs AW, Vigneault F, Atwal GS (2019) Single T cell sequencing demonstrates the functional role of alphabeta TCR pairing in cell lineage and antigen specificity. Front Immunol 10:1516. https://doi.org/10.3389/fimmu.2019.01516
Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21(5):524–529. https://doi.org/10.1038/nm.3833
Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ (2015) Tuning Sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res 75(17):3505–3518. https://doi.org/10.1158/0008-5472.CAN-15-0139
Cho SF, Anderson KC, Tai YT (2018a) Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of bcma-based immunotherapy. Front Immunol 9:1821. https://doi.org/10.3389/fimmu.2018.01821
Cho JH, Collins JJ, Wong WW (2018b) Universal chimeric antigen receptors for multiplexed and logical control of t cell responses. Cell 173(6):1426–1438. https://doi.org/10.1016/j.cell.2018.03.038
Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, Sangiolo D, Todorovic M, Giachino C, Cignetti A (2009) T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum Gene Ther 20(12):1576–1588. https://doi.org/10.1089/hum.2009.117
Clauss J, Obenaus M, Miskey C, Ivics Z, Izsvak Z, Uckert W, Bunse M (2018) Efficient non-viral t-cell engineering by sleeping beauty minicircles diminishing DNA toxicity and miRNAs silencing the endogenous t-cell receptors. Hum Gene Ther 29(5):569–584. https://doi.org/10.1089/hum.2017.136
Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI (1999b) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163(1):507–513
Clay TM, Custer MC, Spiess PJ, Nishimura MI (1999a) Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathol Oncol Res 5(1):3–15
Cohen AD (2018) CAR T cells and other cellular therapies for multiple myeloma: 2018 Update. Am Soc Clin Oncol Educ Book 38:e6–e15. https://doi.org/10.1200/EDBK_200889
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC (2019) B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129(6):2210–2221. https://doi.org/10.1172/JCI126397
Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2015) Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125(10):3981–3991. https://doi.org/10.1172/JCI82416
Cohen CJ, Li YF, El Gamil M, Robbins PF, Rosenberg SA, Morgan RA (2007) Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 67(8):3898–3903
Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA (2006) Enhanced antitumor activity of murine-human hybrid t-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66(17):8878–8886
Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA (2005) Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. JImmunol 175(9):5799–5808. https://doi.org/10.4049/jimmunol.175.9.5799
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14(2):135–146. https://doi.org/10.1038/nrc3670
Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. JImmunother 33(8):780–788. https://doi.org/10.1097/CJI.0b013e3181ee6675
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949
D'Agostino M, Raje N (2020) Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia 34(1):21–34. https://doi.org/10.1038/s41375-019-0669-4
Danhof S, Hudecek M, Smith EL (2018) CARs and other T cell therapies for MM: The clinical experience. Best Pract ResClinHaematol 31(2):147–157. https://doi.org/10.1016/j.beha.2018.03.002
Daniel-Meshulam I, Horovitz-Fried M, Cohen CJ (2013) Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int J Cancer 133(12):2903–2913. https://doi.org/10.1002/ijc.28320
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra225. https://doi.org/10.1126/scitranslmed.3008226
Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA (2010) Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res 16(23):5852–5861. https://doi.org/10.1158/1078-0432.CCR-10-1280
Davoodzadeh GM, Kardar GA, Saeedi Y, Heydari S, Garssen J, Falak R (2017) Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 322:1–14. https://doi.org/10.1016/j.cellimm.2017.10.002
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 8(2):e180–e190. https://doi.org/10.1016/S2214-109X(19)30488-7
De Re V, Caggiari L, De Zorzi M, Fanotto V, Miolo G, Puglisi F, Cannizzaro R, Canzonieri V, Steffan A, Farruggia P, Lopci E, d’Amore ESG, Burnelli R, Mussolin L, Mascarin M (2020) Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infect Agent Cancer 15:42. https://doi.org/10.1186/s13027-020-00307-6
de Waal MR, Yssel H, de Vries JE (1993) Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150(11):4754–4765
Debets R, Donnadieu E, Chouaib S, Coukos G (2016) TCR-engineered T cells to treat tumors: seeing but not touching? Semin Immunol 28(1):10–21. https://doi.org/10.1016/j.smim.2016.03.002
Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H, Steinmetz M (1986) Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320(6059):232–238
Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA (2016) Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the sleeping beauty transposon/transposase system. Mol Ther 24(6):1078–1089. https://doi.org/10.1038/mt.2016.51
Di SA, De AB, Savoldo B (2010) Gene therapy to improve migration of T cells to the tumor site. Methods Mol Biol 651:103–118. https://doi.org/10.1007/978-1-60761-786-0_7
Di SA, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673–1683. https://doi.org/10.1056/NEJMoa1106152
Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26(4):332–342. https://doi.org/10.1097/00002371-200307000-00005
Eisenberg V, Hoogi S, Shamul A, Barliya T, Cohen CJ (2019) T-cells “a la CAR-T(e)”–Genetically engineering T-cell response against cancer. Adv Drug Deliv Rev 141:23–40. https://doi.org/10.1016/j.addr.2019.01.007
Eisenberg V, Shamalov K, Meir S, Hoogi S, Sarkar R, Pinker S, Markel G, Porgador A, Cohen CJ (2017) Targeting multiple tumors using t-cells engineered to express a natural cytotoxicity receptor 2-based chimeric receptor. Front Immunol 8:1212. https://doi.org/10.3389/fimmu.2017.01212
Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP (2020) Ready for repair? Gene editing enters the clinic for the treatment of human disease. Mol Ther Methods Clin Dev 18:532–557. https://doi.org/10.1016/j.omtm.2020.06.022
Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gonen M, Sadelain M (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543(7643):113–117. https://doi.org/10.1038/nature21405
Fahlen L, Read S, Gorelik L, Hurst SD, Coffman RL, Flavell RA, Powrie F (2005) T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 201(5):737–746. https://doi.org/10.1084/jem.20040685
Fedorov VD, Themeli M, Sadelain M (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5(215):215ra172. https://doi.org/10.1126/scitranslmed.3006597
Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M (2019) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. NatMed 25(1):82–88. https://doi.org/10.1038/s41591-018-0290-5
Fichtner AS, Ravens S, Prinz I (2020) Human gammadelta TCR repertoires in health and disease. Cell 9(4):800. https://doi.org/10.3390/cells9040800
Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM (2008) Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 31(5):500–505. https://doi.org/10.1097/CJI.0b013e318177092b
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24(5):563–571. https://doi.org/10.1038/s41591-018-0010-1
Frecha C, Levy C, Cosset FL, Verhoeyen E (2010) Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther 18(10):1748–1757. https://doi.org/10.1038/mt.2010.178
Frezza C (2020) Metabolism and cancer: the future is now. Br J Cancer 122(2):133–135. https://doi.org/10.1038/s41416-019-0667-3
Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. NatRevCancer 12(4):298–306
Garetto S, Sardi C, Martini E, Roselli G, Morone D, Angioni R, Cianciotti BC, Trovato AE, Franchina DG, Castino GF, Vignali D, Erreni M, Marchesi F, Rumio C, Kallikourdis M (2016) Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Oncotarget 7(28):43010–43026. https://doi.org/10.18632/oncotarget.9280
Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15(7):808–813
Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ (1995) Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13(8):1939–1949
Goff SL, Johnson LA, Black MA, Xu H, Zheng Z, Cohen CJ, Morgan RA, Rosenberg SA, Feldman SA (2010) Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother 59(10):1551–1560
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19–20):1267–1284. https://doi.org/10.1101/gad.314617.118
Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22(4):433–438. https://doi.org/10.1038/nm.4051
Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA (2014) PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124(5):2246–2259. https://doi.org/10.1172/JCI73639
Gupta SS, Wang J, Chen M (2020) Metabolic reprogramming in CD8(+) T cells during acute viral infections. Front Immunol 11:1013. https://doi.org/10.3389/fimmu.2020.01013
Gutierrez-Guerrero A, Cosset FL, Verhoeyen E (2020) Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy. Viruses 12(9):1016. https://doi.org/10.3390/v12091016
Haas L, Obenauf AC (2019) Allies or enemies-the multifaceted role of myeloid cells in the tumor microenvironment. Front Immunol 10:2746. https://doi.org/10.3389/fimmu.2019.02746
Haga-Friedman A, Horovitz-Fried M, Cohen CJ (2012) Incorporation of transmembrane hydrophobic mutations in the tcr enhance its surface expression and t cell functional avidity. J Immunol 188(11):5538–5546
Haslam A, Prasad V (2019) Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, Murphy A, Chauhan D, Higgins LS, Anderson KC (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10(22):7540–7546. https://doi.org/10.1158/1078-0432.CCR-04-0632
He Q, Jiang X, Zhou X, Weng J (2019) Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol 12(1):139. https://doi.org/10.1186/s13045-019-0812-8
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS (2020) Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med 26(11):1686–1690. https://doi.org/10.1038/s41591-020-1074-2
Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N (2013) Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21(11):2087–2101. https://doi.org/10.1038/mt.2013.185
Heidegger I, Pircher A, Pichler R (2019) Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 9:490. https://doi.org/10.3389/fonc.2019.00490
Helmy KY, Patel SA, Nahas GR, Rameshwar P (2013) Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv 4(10):1307–1320. https://doi.org/10.4155/tde.13.88
Hickman ES, Lomax ME, Jakobsen BK (2016) Antigen selection for enhanced affinity t-cell receptor-based cancer therapies. J Biomol Screen 21(8):769–785. https://doi.org/10.1177/1087057116637837
Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP (2011) Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117(3):808–814. https://doi.org/10.1182/blood-2010-05-286286
Hoogi S, Eisenberg V, Mayer S, Shamul A, Barliya T, Cohen CJ (2019) A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. J Immunother Cancer 7(1):243. https://doi.org/10.1186/s40425-019-0721-y
Howie B, Sherwood AM, Berkebile AD, Berka J, Emerson RO, Williamson DW, Kirsch I, Vignali M, Rieder MJ, Carlson CS, Robins HS (2015) High-throughput pairing of T cell receptor alpha and beta sequences. Sci Transl Med 7(301):301ra131. https://doi.org/10.1126/scitranslmed.aac5624
Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24(6):1160–1170. https://doi.org/10.1038/leu.2010.75
Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA (2005) Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 175(11):7226–7234. https://doi.org/10.4049/jimmunol.175.11.7226
Huang JJ, Blobe GC (2016) Dichotomous roles of TGF-beta in human cancer. Biochem Soc Trans 44(5):1441–1454. https://doi.org/10.1042/BST20160065
Huettner C, Paulus W, Roggendorf W (1994) Increased amounts of IL-10 mRNA in anaplastic astrocytomas and glioblastoma multiforme. Verh Dtsch Ges Pathol 78:418–422
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S (2020) Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 4(15):3776–3787. https://doi.org/10.1182/bloodadvances.2020002509
Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177(9):6548–6559. https://doi.org/10.4049/jimmunol.177.9.6548
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, Van Waes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3):535–546. https://doi.org/10.1182/blood-2009-03-211714
Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, Zhao Y, Abad J, Zheng Z, Rosenberg SA, Morgan RA (2009) Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum Gene Ther 20(6):630–640. https://doi.org/10.1089/hum.2008.048
Joyce JJ III (1988) History of the arthroscopy Association of North America, its origin and growth: part II. Arthroscopy 4(1):1–4. https://doi.org/10.1016/s0749-8063(88)80002-1
Jurgens B, Clarke NS (2019) Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat Biotechnol 37(4):370–375. https://doi.org/10.1038/s41587-019-0083-5
Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ (2016) Phase i trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363–3376. https://doi.org/10.1172/JCI86721
Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P (2002) Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 13(16):1971–1980. https://doi.org/10.1089/10430340260355374
Kessels HW, Wolkers MC, van der Valk MA, Schumacher TN (2001) Immunotherapy through TCR gene transfer. Nat Immunol 2(10):957–961
Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP (2016) Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest 126(1):318–334. https://doi.org/10.1172/JCI81217
Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31(1):71–75. https://doi.org/10.1038/nbt.2459
Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH (2018) Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. MolTher 26(7):1855–1866. https://doi.org/10.1016/j.ymthe.2018.05.003
Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ (2015a) A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 13:102. https://doi.org/10.1186/s12967-015-0460-x
Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ (2015b) IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Onco Targets Ther 4(3):e994446. https://doi.org/10.4161/2162402X.2014.994446
Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13(6):472–482. https://doi.org/10.1016/j.ccr.2008.05.005
Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, Greenberg PD (2007) Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109(6):2331–2338
Lai J, Wang Y, Wu SS, Ding D, Sun ZY, Zhang Y, Zhou J, Zhou Z, Xu YC, Pan LQ, Chen SQ (2018) Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials 178:158–169. https://doi.org/10.1016/j.biomaterials.2018.06.017
Larson C, Oronsky B, Carter CA, Oronsky A, Knox SJ, Sher D, Reid TR (2020) TGF-beta: a master immune regulator. Expert Opin Ther Targets 24(5):427–438. https://doi.org/10.1080/14728222.2020.1744568
Lebrun JJ (2012) The dual role of tgfbeta in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol 2012:381428. https://doi.org/10.5402/2012/381428
Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. Cancers (Basel) 3(4):3856–3893. https://doi.org/10.3390/cancers3043856
Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF (2014) Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 22(6):1211–1220. https://doi.org/10.1038/mt.2014.47
Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK (2018) CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood 131(3):311–322. https://doi.org/10.1182/blood-2017-05-787598
Lemal R, Tournilhac O (2019) State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. JImmunotherCancer 7(1):202. https://doi.org/10.1186/s40425-019-0686-x
Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103(46):17372–17377. https://doi.org/10.1073/pnas.0608138103
Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, Han X, Wang P (2017) Enhanced cancer immunotherapy by chimeric antigen receptor-modified t cells engineered to secrete checkpoint inhibitors. Clin Cancer Res 23(22):6982–6992. https://doi.org/10.1158/1078-0432.CCR-17-0867
Lim AR, Rathmell WK, Rathmell JC (2020) The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. elife 9. https://doi.org/10.7554/eLife.55185
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6):863–871. https://doi.org/10.1182/blood-2013-03-490565
Linnemann C, Schumacher TN, Bendle GM (2011) T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol 131(9):1806–1816
Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, Zhou L, Loew A, Young RM, June CH, Zhao Y (2015) Affinity-tuned Erb B2 or EGFR chimeric antigen receptor T Cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 75(17):3596–3607. https://doi.org/10.1158/0008-5472.CAN-15-0159
Lo Presti V, Buitenwerf F, van Til NP, Nierkens S (2020) Gene augmentation and editing to improve TCR engineered T cell therapy against solid tumors. Vaccines (Basel) 8(4):733. https://doi.org/10.3390/vaccines8040733
Lo AS, Taylor JR, Farzaneh F, Kemeny DM, Dibb NJ, Maher J (2008) Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Mol Immunol 45(5):1276–1287. https://doi.org/10.1016/j.molimm.2007.09.010
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31–42. https://doi.org/10.1016/S1470-2045(18)30864-7
Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277(26):23111–23115. https://doi.org/10.1074/jbc.M202487200
Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y (2016) Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A 113(4):E450–E458. https://doi.org/10.1073/pnas.1524193113
Ma T, Shi J, Liu H (2019) Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ann Hematol 98(4):813–822. https://doi.org/10.1007/s00277-018-03592-9
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A (2020) Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest 130(11):6021–6033. https://doi.org/10.1172/JCI138473
Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M (2020) Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol 11:2105. https://doi.org/10.3389/fimmu.2020.02105
Manfredi F, Cianciotti BC, Potenza A, Tassi E, Noviello M, Biondi A, Ciceri F, Bonini C, Ruggiero E (2020) TCR redirected t cells for cancer treatment: achievements, hurdles, and goals. Front Immunol 11:1689. https://doi.org/10.3389/fimmu.2020.01689
Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z, Ramon J, Schachter J (2009) Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res 29(1):145–154
Markley JC, Sadelain M (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115(17):3508–3519. https://doi.org/10.1182/blood-2009-09-241398
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De MB, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448. https://doi.org/10.1056/NEJMoa1709866
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1(1):26–31. https://doi.org/10.1158/2326-6066.CIR-13-0006
Meir R, Shamalov K, Betzer O, Motiei M, Horovitz-Fried M, Yehuda R, Popovtzer A, Popovtzer R, Cohen CJ (2015) Nanomedicine for cancer immunotherapy: tracking cancer-specific T-cells in vivo with gold nanoparticles and ct imaging. ACS Nano 9(6):6363–6372. https://doi.org/10.1021/acsnano.5b01939
Meir R, Shamalov K, Sadan T, Motiei M, Yaari G, Cohen CJ, Popovtzer R (2017) Fast image-guided stratification using anti-programmed death ligand 1 gold nanoparticles for cancer immunotherapy. ACS Nano 11(11):11127–11134. https://doi.org/10.1021/acsnano.7b05299
Merhavi-Shoham E, Haga-Friedman A, Cohen CJ (2012) Genetically modulating T-cell function to target cancer. Semin Cancer Biol 22(1):14–22
Meril S, Harush O, Reboh Y, Matikhina T, Barliya T, Cohen CJ (2020) Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells. Mol Carcinog 59(7):713–723. https://doi.org/10.1002/mc.23213
Mier JW (2019) The tumor microenvironment in renal cell cancer. Curr Opin Oncol 31(3):194–199. https://doi.org/10.1097/CCO.0000000000000512
Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, Panjwani S, Gray KD, Tassler AB, Zarnegar R, Fahey TJ 3rd, Jin MM (2017) CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin Cancer Res 23(24):7569–7583. https://doi.org/10.1158/1078-0432.CCR-17-2008
Moco PD, de Abreu Neto MS, Fantacini DMC, Picanco-Castro V (2020) Optimized production of lentiviral vectors for CAR-T cell. Methods Mol Biol 2086:69–76. https://doi.org/10.1007/978-1-0716-0146-4_5
Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF (2017) Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 25(1):249–258. https://doi.org/10.1016/j.ymthe.2016.10.016
Mondino A, Vella G, Icardi L (2017) Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors. Cytokine Growth Factor Rev 36:57–65. https://doi.org/10.1016/j.cytogfr.2017.06.006
Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH, Albelda SM (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14):4719–4730. https://doi.org/10.1158/1078-0432.CCR-11-0351
Morath A, Schamel WW (2020) alphabeta and gammadelta T cell receptors: similar but different. J Leukoc Biol 107(6):1045–1055. https://doi.org/10.1002/JLB.2MR1219-233R
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851. https://doi.org/10.1038/mt.2010.24
Mori N, Prager D (1998) Interleukin-10 gene expression and adult T-cell leukemia. Leuk Lymphoma 29(3–4):239–248. https://doi.org/10.3109/10428199809068561
Morris EC, Neelapu SS, Giavridis T, Sadelain M (2021) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. https://doi.org/10.1038/s41577-021-00547-6
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705–716. https://doi.org/10.1056/NEJMoa2024850
Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138(3):989–995
Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanovic S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS (2021) TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med 27(3):419–425. https://doi.org/10.1038/s41591-020-01225-1
Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K (2019) Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci 110(10):3079–3088. https://doi.org/10.1111/cas.14169
Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol Off J Am Soc Clin Oncol 38(27):3119–3128. https://doi.org/10.1200/JCO.19.02104
Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A, Zhang B, Boross-Harmer S, Cipollone J, Nelles M, Scheid E, Fyrsta M, Lo CS, Nie J, Yam JY, Yen PH, Gray D, Motta V, Elford AR, DeLuca S, Wang L, Effendi S, Ellenchery R, Hirano N, Ohashi PS, Butler MO (2019) Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother 68(5):773–785. https://doi.org/10.1007/s00262-019-02307-x
Nowicki TS, Farrell C, Morselli M, Rubbi L, Campbell KM, Macabali MH, Berent-Maoz B, Comin-Anduix B, Pellegrini M, Ribas A (2020) Epigenetic suppression of transgenic T-cell receptor expression via gamma-retroviral vector methylation in adoptive cell transfer therapy. Cancer Discov 10(11):1645–1653. https://doi.org/10.1158/2159-8290.CD-20-0300
Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, Kato I (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69(23):9003–9011
Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL (2020) Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large b cell lymphoma. Biol Blood Marrow Transplant 26(9):1581–1588. https://doi.org/10.1016/j.bbmt.2020.06.008
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662):217–221. https://doi.org/10.1038/nature22991
Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT (2020) In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun 11(1):6080. https://doi.org/10.1038/s41467-020-19486-2
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YS, Min IM, Jin MM (2017) Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep 7(1):14366. https://doi.org/10.1038/s41598-017-14749-3
Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, Rosenberg SA (2017) Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Cancer Res 23(10):2491–2505. https://doi.org/10.1158/1078-0432.CCR-16-2680
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620–626. https://doi.org/10.1038/mt.2010.272
Pearson RM, Casey LM, Hughes KR, Miller SD, Shea LD (2017) In vivo reprogramming of immune cells: technologies for induction of antigen-specific tolerance. Adv Drug Deliv Rev 114:240–255. https://doi.org/10.1016/j.addr.2017.04.005
Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA (2009) Efficient nonviral sleeping beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 16(8):1042–1049. https://doi.org/10.1038/gt.2009.54
Picanco-Castro V, Goncalves PC, Swiech K, Ribeiro Malmegrim KC, Tadeu CD, Silveira PG (2020) Emerging CAR T cell therapies: clinical landscape and patent technological routes. Hum Vaccin Immunother 16(6):1424–1433. https://doi.org/10.1080/21645515.2019.1689744
Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M, Comstock ML, Rajan A, Patel BKR, Voutsinas JM, Wu Q, Liu L, Cowan AJ, Wood BL, Green DJ, Riddell SR (2019) gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134(19):1585–1597. https://doi.org/10.1182/blood.2019000050
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139. https://doi.org/10.1126/scitranslmed.aac5415
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733. https://doi.org/10.1056/NEJMoa1103849
Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF (2016) Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol Res 4(8):669–678. https://doi.org/10.1158/2326-6066.CIR-15-0215
Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18(7):805–815
Qin W, Tian F, Wang F, Song B, Wang H, Zhang Q, Jovanovic B, Liang L, Guo Y, Smith N, Lee C (2008) Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors. Urology 72(4):943–947. https://doi.org/10.1016/j.urology.2008.04.017
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18(1):155. https://doi.org/10.1186/s12943-019-1091-2
Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS (2012) T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFbeta) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med 10:127. https://doi.org/10.1186/1479-5876-10-127
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9):847–856. https://doi.org/10.1038/nbt.4195
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. Paper presented at the N Engl J Med New England Journal of Medicine, 2019
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH (2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21(8):914–921. https://doi.org/10.1038/nm.3910
Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8(5):615–623
Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281. https://doi.org/10.1038/nri3191
Ribas A (2015) Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 5(9):915–919. https://doi.org/10.1158/2159-8290.CD-15-0563
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355. https://doi.org/10.1126/science.aar4060
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG (2013) T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121(9):1612–1621. https://doi.org/10.1182/blood-2012-09-457531
Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM (2000) Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer 86(6):818–826. https://doi.org/10.1002/(sici)1097-0215(20000615)86:6<818::aid-ijc10>3.0.co;2-w
Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21(5):1019–1027. https://doi.org/10.1158/1078-0432.CCR-14-2708
Robbins PF, Li YF, El Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA (2008) Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 180(9):6116–6131
Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS (2016) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A 113(4):E459–E468. https://doi.org/10.1073/pnas.1524155113
Roex G, Feys T, Beguin Y, Kerre T, Poire X, Lewalle P, Vandenberghe P, Bron D, Anguille S (2020) Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics 12(2):194. https://doi.org/10.3390/pharmaceutics12020194
Rosenberg SA (2014) Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment. Nat Rev Clin Oncol 11(11):630–632. https://doi.org/10.1038/nrclinonc.2014.174
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550–4557. https://doi.org/10.1158/1078-0432.CCR-11-0116
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126(10):3814–3826. https://doi.org/10.1172/JCI87366
Sadio F, Stadlmayr G, Stadlbauer K, Graf M, Scharrer A, Ruker F, Wozniak-Knopp G (2020) Stabilization of soluble high-affinity T-cell receptor with de novo disulfide bonds. FEBS Lett 594(3):477–490. https://doi.org/10.1002/1873-3468.13616
Saito T, Hochstenbach F, Marusic-Galesic S, Kruisbeek AM, Brenner M, Germain RN (1988) Surface expression of only gamma delta and/or alpha beta T cell receptor heterodimers by cells with four (alpha, beta, gamma, delta) functional receptor chains. J Exp Med 168(3):1003–1020
Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G (2012) CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother 61(10):1833–1847. https://doi.org/10.1007/s00262-012-1245-1
Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2(8):1383–1390
Schlenker R, Olguin-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Ruhland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E (2017) Chimeric PD-1:28 receptor upgrades low-avidity t cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy. Cancer Res 77(13):3577–3590. https://doi.org/10.1158/0008-5472.CAN-16-1922
Schouppe E, De BP, Van Ginderachter JA, Sarukhan A (2012) Instruction of myeloid cells by the tumor microenvironment: open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Onco Targets Ther 1(7):1135–1145. https://doi.org/10.4161/onci.21566
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak O, Salles G, Maziarz RT (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med 380(1):45–56. https://doi.org/10.1056/NEJMoa1804980
Sebestyen Z, Schooten E, Sals T, Zaldivar I, San Jose E, Alarcon B, Bobisse S, Rosato A, Szollosi J, Gratama JW, Willemsen RA, Debets R (2008) Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol 180(11):7736–7746
Shamalov K, Levy SN, Horovitz-Fried M, Cohen CJ (2017) The mutational status of p53 can influence its recognition by human T-cells. Onco Targets Ther 6(4):e1285990. https://doi.org/10.1080/2162402X.2017.1285990
Shyer JA, Flavell RA, Bailis W (2020) Metabolic signaling in T cells. Cell Res 30(8):649–659. https://doi.org/10.1038/s41422-020-0379-5
Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P (2016) Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer 4:21. https://doi.org/10.1186/s40425-016-0125-1
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8):615–625
Singh N, Shi J, June CH, Ruella M (2017) Genome-editing technologies in adoptive T cell immunotherapy for cancer. Curr Hematol Malig Rep 12(6):522–529. https://doi.org/10.1007/s11899-017-0417-7
Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, Strieter RM (1994) Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 145(1):18–25
Sommermeyer D, Uckert W (2010) Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 184(11):6223–6231
Son B, Lee S, Youn H, Kim E, Kim W, Youn B (2017) The role of tumor microenvironment in therapeutic resistance. Oncotarget 8(3):3933–3945. https://doi.org/10.18632/oncotarget.13907
Spear TT, Evavold BD, Baker BM, Nishimura MI (2019) Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy. Cancer Immunol Immunother 68(11):1881–1889. https://doi.org/10.1007/s00262-019-02401-0
Spear TT, Foley KC, Garrett-Mayer E, Nishimura MI (2018) TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. J Leukoc Biol 103(5):973–983. https://doi.org/10.1002/JLB.5A0817-314R
Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C, Riddell SR (2019) Logic-Gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35(3):489–503 e488. https://doi.org/10.1016/j.ccell.2019.02.003
Stanton SE, Disis ML (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4:59. https://doi.org/10.1186/s40425-016-0165-6
Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Grunewald TGP, Kobold S, Busch DH, Jeremias I, Blaeschke F, Feuchtinger T (2020) Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood 136(12):1407–1418. https://doi.org/10.1182/blood.2020005185
Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33(14):1543–1550. https://doi.org/10.1200/JCO.2014.58.9093
Stevanovic S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS (2019) A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res 25(5):1486–1493. https://doi.org/10.1158/1078-0432.CCR-18-2722
Stone JD, Harris DT, Kranz DM (2015) TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol 33:16–22. https://doi.org/10.1016/j.coi.2015.01.003
Tal Y, Yaakobi S, Horovitz-Fried M, Safyon E, Rosental B, Porgador A, Cohen CJ (2014) An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget 5(21):10949–10958
Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S, Chi Z, Guo J (2019) Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol 12(1):7. https://doi.org/10.1186/s13045-018-0693-2
Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell DJ Jr, Dudley ME, Morgan RA, Rosenberg SA (2008) Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther 19(11):1219–1232. https://doi.org/10.1089/hum.2008.083
Tian Y, Cox MA, Kahan SM, Ingram JT, Bakshi RK, Zajac AJ (2016) A context-dependent role for IL-21 in modulating the differentiation, distribution, and abundance of effector and memory CD8 T Cell subsets. J Immunol 196(5):2153–2166. https://doi.org/10.4049/jimmunol.1401236
Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S (2019) Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front Immunol 10:1613. https://doi.org/10.3389/fimmu.2019.01613
Tran Q, Lee H, Park J, Kim SH, Park J (2016a) Targeting cancer metabolism–revisiting the warburg effects. Toxicol Res 32(3):177–193. https://doi.org/10.5487/TR.2016.32.3.177
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA (2016b) T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375(23):2255–2262. https://doi.org/10.1056/NEJMoa1609279
Tran E, Robbins PF, Rosenberg SA (2017) ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18(3):255–262. https://doi.org/10.1038/ni.3682
Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641–645. https://doi.org/10.1126/science.1251102
Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME (2008) Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31(8):742–751
Treisman J, Hwu P, Minamoto S, Shafer GE, Cowherd R, Morgan RA, Rosenberg SA (1995) Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85(1):139–145
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG (2017) Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 35(26):3010–3020. https://doi.org/10.1200/JCO.2017.72.8519
Uckert W, Schumacher TN (2009) TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother 58(5):809–822. https://doi.org/10.1007/s00262-008-0649-4
Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr (2012) A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 72(7):1844–1852. https://doi.org/10.1158/0008-5472.CAN-11-3890
van den Berg JH, Heemskerk B, Gomez-Eerland R, Michels S, NAM B, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M, van der Hage JA, MWJM W, Pronk LM, Geukes Foppen MH, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, JBAG H (2020) Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer 8(2):e000848. https://doi.org/10.1136/jitc-2020-000848
van der Veken LT, Coccoris M, Swart E, Falkenburg JH, Schumacher TN, Heemskerk MH (2009) Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol 182(1):164–170
Vaupel P, Schmidberger H, Mayer A (2019) The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol 95(7):912–919. https://doi.org/10.1080/09553002.2019.1589653
Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G (2009) Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17(5):880–888. https://doi.org/10.1038/mt.2009.34
Vigneron N (2015) Human tumor antigens and cancer immunotherapy. Biomed Res Int 2015:948501. https://doi.org/10.1155/2015/948501
Vihervuori H, Autere TA, Repo H, Kurki S, Kallio L, Lintunen MM, Talvinen K, Kronqvist P (2019) Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer. J Cancer Res Clin Oncol 145(12):3105–3114. https://doi.org/10.1007/s00432-019-03036-5
Vogler I, Newrzela S, Hartmann S, Schneider N, Koehl U, Grez M (2010) An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther 18(7):1330–1338. https://doi.org/10.1038/mt.2010.83
Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56(23):5499–5505
Voss RH, Willemsen RA, Kuball J, Grabowski M, Engel R, Intan RS, Guillaume P, Romero P, Huber C, Theobald M (2008) Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol 180(1):391–401
Vuong L, Kotecha RR, Voss MH, Hakimi AA (2019) Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov 9(10):1349–1357. https://doi.org/10.1158/2159-8290.CD-19-0499
Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahl LM, Ellingsworth L, Schmidt JA, Hall G, Roberts AB (1988) Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 140(9):3026–3032
Waldmann TA, Dubois S, Miljkovic MD, Conlon KC (2020) IL-15 in the combination immunotherapy of cancer. Front Immunol 11:868. https://doi.org/10.3389/fimmu.2020.00868
Walia V, Mu EW, Lin JC, Samuels Y (2012) Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res 25(2):155–170
Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P (2018) NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res 78(4):1031–1043. https://doi.org/10.1158/0008-5472.CAN-17-1788
Weizman E, Cohen CJ (2016) Engineering T-cell specificity genetically to generate anti-melanoma reactivity. Methods Mol Biol. https://doi.org/10.1007/7651_2015_297
Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, van der Stegen SJ, Spicer JF, Davies DM, Maher J (2010) Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 285(33):25538–25544. https://doi.org/10.1074/jbc.M110.127951
Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology 12(11):1113–1125. https://doi.org/10.1093/neuonc/noq082
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, Wu J, Wang Y, Wang J, Yan H, Xu WB, Jiang H, Du J, Ding XY, Li B, Li JM, Fu WJ, Zhu J, Zhu L, Chen Z, Fan XF, Hou J, Li JY, Mi JQ, Chen SJ (2019) Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A 116(19):9543–9551. https://doi.org/10.1073/pnas.1819745116
Yamamoto TN, Kishton RJ, Restifo NP (2019) Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat Med. https://doi.org/10.1038/s41591-019-0596-y
Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L, Jing G, Sang W, Zhu F, Chen W, Wu Q, Yao Y, Wang G, Zhao J, Zheng J, Li Z, Xu K (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6(10):e521–e529. https://doi.org/10.1016/S2352-3026(19)30115-2
Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, Zheng Z, Jones S, Restifo NP, Rosenberg SA, Morgan RA (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15(21):1411–1423. https://doi.org/10.1038/gt.2008.90
Yu JX, Upadhaya S, Tatake R, Barkalow F, Hubbard-Lucey VM (2020) Cancer cell therapies: the clinical trial landscape. Nat Rev Drug Discov 19(9):583–584. https://doi.org/10.1038/d41573-020-00099-9
Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24(6):724–730. https://doi.org/10.1038/s41591-018-0040-8
Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19(4):751–759. https://doi.org/10.1038/mt.2010.313
Zhang J, Wang L (2019) The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. Technol Cancer Res Treat 18:1533033819831068. https://doi.org/10.1177/1533033819831068
Zhang T, Wu MR, Sentman CL (2012) An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol 189(5):2290–2299
Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA (2013) Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 20(5):575–580. https://doi.org/10.1038/gt.2012.75
Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA (2007) High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 179(9):5845–5854
Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG (2018) A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 11(1):141. https://doi.org/10.1186/s13045-018-0681-6
Zidlik V, Bezdekova M, Brychtova S (2020) Tumor infiltrating lymphocytes in malignant melanoma–allies or foes? Biomed Pap Med FacUniv Palacky Olomouc Czech Repub 164(1):43–48. https://doi.org/10.5507/bp.2019.048
Zikich D, Schachter J, Besser MJ (2016) Predictors of tumor-infiltrating lymphocyte efficacy in melanoma. Immunotherapy 8(1):35–43. https://doi.org/10.2217/imt.15.99
Zorro MM, Aguirre-Gamboa R, Mayassi T, Ciszewski C, Barisani D, Hu S, Weersma RK, Withoff S, Li Y, Wijmenga C, Jabri B, Jonkers IH (2020) Tissue alarmins and adaptive cytokine induce dynamic and distinct transcriptional responses in tissue-resident intraepithelial cytotoxic T lymphocytes. J Autoimmun 108:102422. https://doi.org/10.1016/j.jaut.2020.102422
Zur HH (2009) The search for infectious causes of human cancers: where and why. Virology 392(1):1–10
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zur, R.T., Adler, G., Shamalov, K., Tal, Y., Ankri, C., Cohen, C.J. (2022). Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. In: Klink, M., Szulc-Kielbik, I. (eds) Interaction of Immune and Cancer Cells. Experientia Supplementum, vol 113. Springer, Cham. https://doi.org/10.1007/978-3-030-91311-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-91311-3_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-91310-6
Online ISBN: 978-3-030-91311-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)